12:09 PM EST - Medicure : Announced that pitavastatin magnesium (ZYPITAMAGTM) tablets are now available in retail pharmacies throughout the United States. ZYPITAMAGTM, a statin (HMG-CoA reductase inhibitor) medication approved by the U.S. Food and Drug Administration (FDA) in July 2017, is available in strengths of 1 mg, 2 mg and 4 mg. ZYPITAMAGTM is indicated for the treatment of patients with primary hyperlipidemia or mixed dyslipidemia as an adjunctive therapy to diet, to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C). Medicure
shares V.MPH are trading unchanged at $6.48.